Effect of l-ornithine-l-aspartate therapy on the hyperammonemia level and results of the number connection test of patients suffering from nonalcoholic fatty liver disease

Кизова, Е. А.; Потехина, Ю. П.

doi:10.31146/1682-8658-ecg-169-9-80-84

Cited by 5 publications

(2 citation statements)

References 11 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Th e duration of treatment depends on various factors, and it may be required over a long term. Th e use of LOLA in patients with liver failure and HE improves the function of hepatocytes as well as neurons [102].…”

Section: L-ornithinementioning

confidence: 99%

Russian Consensus on “Hyperammonemia in Adults”: The 2021 Version (in English)

Лазебник

Голованова

Алексеенко

et al. 2022

jour

View full text Add to dashboard Cite

Hyperammonemia is an acute or chronic intoxication with ammonia and ammonium associated with elevated ammonia levels in serum due to either its increased production and/or decreased detoxification. Hyperammonemia can result from a variety of causes and clinically presents with unspecific signs and symptoms, including asthenia, encephalopathy, liver steatosis or fibrosis, and sarcopenia. With impaired liver function, hyperammonemia most frequently manifests in (micro)encephalopathy. Thus in case of unexpect change in mental status hyperammonemia must be excluded as fast as possible. An express method of photometric assay is informative enough to determine the ammonia levels. The following hyperammonemia classification is proposed: a) by ammonia levels (normal level: ≤ 60 μmol/L; mild (Grade 1): ≤ 100 μmol/L; moderate (Grade 2): ≤ 200 μmol/L; and severe (Grade 3): > 200 μmol/L); b) by etiopathogenesis (hereditary (congenital), functional (physiological), acquired (hepatic, extrahepatic, mixed)); c) by clinical presentation (transient, recurrent or persistent, constant (stable, without treatment), covert). Treatment for hyperammonemia is aimed at treating the primary disease and includes a diet that is restricted in animal protein but contains sufficient vegetable protein, limited physical activities, and use of intestinal non-absorbable antibiotics (rifaximin- alpha) as well as pre- and probiotics. L-ornithine- L-aspartate (LOLA) is a baseline therapeutic product administered in a number of scenarios to correct the level of hyperammonemia.

show abstract

Section: L-ornithinementioning

confidence: 99%

Russian Consensus on “Hyperammonemia in Adults”: The 2021 Version (in English)

Лазебник

Голованова

Алексеенко

et al. 2022

jour

View full text Add to dashboard Cite

show abstract

“…Длительность лечения зависит от многих причин и может продолжаться в течение продолжительного времени. Применение L-орнитина-L-аспартата у больных печеночной недостаточностью и ПЭ улучшает функцию не только гепатоцитов, но и нейронов [102].…”

Section: комментарииunclassified

Russian Consensus “Hyperammonemia in Adults” (Version 2021)

Лазебник

Голованова

Алексеенко

et al. 2021

jour

View full text Add to dashboard Cite

Justification Given the large number of reports on the peculiarities of liver lesions during the Sars-Cov-2 infection [1], a team of experts who participated in the 23rd Congress of the Scientific Society of Gastroenterologists of Russia and 15 National Congress of Therapists of November 19, 2020 decided to make additions to the Russian Consensus of “Hyperammonemia in Adults” published early 2020 [2, 3].

show abstract

Mild post-COVID syndrome in young patients

Ivchenko,

Lobzhanidze,

Rusina

et al. 2023

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Background. Many COVID-19 survivors suffer from post-COVID syndrome, which significantly worsens the quality of life. Its presentation is quite diverse, with cognitive disorders being of particular importance. Liver injury due to the direct virus action and the treatment of the new coronavirus infection can persist for a long time during the recovery period and lead to hyperammonemia, which can cause cognitive disorders, including minimal hepatic encephalopathy. Aim. To study cognitive disorders in post-COVID syndrome and the possibility of their treatment with L-ornithine-L-aspartate. Materials and methods. The study included 30 students from 18 to 24 years old who had COVID-19 and decreased attention, memory impairment, and other cognitive disorders inherent in hepatic encephalopathy of latent (grade 0) or mild (grade 1) severity, without pronounced impairment of intelligence, memory, speech, and learning ability. Hyperammonemia, elevated alanine aminotransferase, aspartate aminotransferase, and -glutamyl transpeptidase, signs of hepatic encephalopathy according to psychometric tests, were reported in young people. All patients in the study were treated with L-ornithine-L-aspartate to correct the ammonia blood level and improve signs of hepatic encephalopathy and the general condition. Results and conclusion. An improvement in the objective findings, liver enzymes, a decrease in ammonia level, and an improvement in testing results for changes in cognitive functions were reported.

show abstract

Effect of l-ornithine-l-aspartate therapy on the hyperammonemia level and results of the number connection test of patients suffering from nonalcoholic fatty liver disease

Cited by 5 publications

References 11 publications

Russian Consensus on “Hyperammonemia in Adults”: The 2021 Version (in English)

Russian Consensus on “Hyperammonemia in Adults”: The 2021 Version (in English)

Russian Consensus “Hyperammonemia in Adults” (Version 2021)

Mild post-COVID syndrome in young patients

Contact Info

Product

Resources

About